Precision AQ

HEOR is at a crossroads—rising expectations, tighter timelines, and commercial pressures require a new approach. How can teams demonstrate their research drives real business impact? In their latest PharmaExec feature, Ross Maclean and John Graham, Pharm.D. dive into the Bookends Approach—a proven framework for aligning HEOR research with business goals without compromising scientific rigor. Learn how to apply the Bookends Approach and turn HEOR insights into action: https://lnkd.in/ecu9JEGf #HEOR #Pharma #ResearchImpact #RealWorldEvidence

Key Takeaways from #WEPA2025: What Pharma Needs to Know 1️⃣ Affordability & Global Pricing Pressures: Governments worldwide are implementing stricter price controls, pushing for greater transparency and enforcing affordability measures. With budget constraints tightening in the US and Europe, pharma companies must rethink global pricing strategies, such as proactively exploring emerging markets like APAC and MENA. With this shift, equitable global pricing models and a clear launch market sequencing strategy to mitigate IRP challenges become imperative for a successful global launch. 2️⃣ Rising HTA & Evidence Expectations: European HTA bodies are raising their evidence requirements for added value recognition and the impact of cross-border initiatives on evidence generation needs is unclear. APAC and MENA regions are evolving, with major pricing and reimbursement policy reforms in established markets (e.g., China, Japan) and emerging markets implementing national HTA processes (e.g., GCC, North Africa). Manufacturers must stay ahead by: ✔️ Adapting early to new local evidence requirements and seeking early stakeholder engagement ✔️ Utilizing AI-driven predictive tools to anticipate hurdles (e.g., EU JCA PICO prediction) ✔️ Leveraging cross-border efficiencies to streamline evidence-generation plans, approvals and pricing discussions 3️⃣ Data-Driven Planning Is No Longer Optional: The rise of multi-indication therapies and upcoming loss of exclusivity (LOE) of multiple blockbuster drugs means that pharma companies must plan for market events earlier than ever. Analytical tools should be integrated ahead of all milestones within a product’s lifecycle to optimise launch sequencing, pricing strategy and access planning- allowing manufacturers to stay ahead of shifting market dynamics. The takeaway? Pharma companies need to think globally, act early and integrate data-driven decision-making at every step. With pricing pressures intensifying, understanding net price transparency is more critical than ever. Dive deeper into the what, how and what now of global net price transparency in our latest blog post: https://lnkd.in/e5s2nxvK #Pharma #MarketAccess #HTA #PricingStrategy

🚨 The AMCP 2025 Annual Meeting is in two weeks 🚨 Our Market Access team is packing their bags and heading to Houston for what promises to be a can’t-miss event. From strategic messaging development to engaging the right stakeholders, we’ll be sharing our industry expertise with those who want to enhance their product coverage and patient access. Book a one-on-one meeting with us between March 31st and April 3rd at and see how our team can help you. https://lnkd.in/eZjhuTUS

When market access teams find a tool that makes their jobs easier, they talk about it. This top med-tech company shared how #AccessGenius is helping them work smarter- simplifying payer insights, surfacing the most relevant information and making complex decisions easier. The best part? It delivers the answers they actually need. ➡️ Swipe through to see what they had to say Curious about how AccessGenius can help your team? Learn more: https://lnkd.in/gn-jJXVF #MarketAccess #PayerInsights #HealthcareStrategy #PrecisionAQ

Mark your calendars for April 2nd from 11:30 to 2:30 CT! 🗓 Our very own Erin Lopata, VP, Director of Precision AQ’s Access Experience Team, is presenting a poster at the AMCP 2025 Annual Meeting. She'll be diving into payer trends in clinical evaluation, financial management, and patient support for orphan drugs. This is a can’t-miss discussion if you’re at #AMCP2025. And be sure to book a one-on-one discussion with one of our market access experts for a personalized plan to help with patient access, omnichannel presence, and so much more: https://lnkd.in/eZjhuTUS

In our upcoming live #webinar on Thursday March 27, join our experts Ruud Kooi, Helen Laurence and Alex Grosvenor as they look at what HCP and industry #insights into engagement in 2024 can tell us about how to better connect with customers in 2025 – supported by highlights from our latest Global Trends Report. https://lnkd.in/ezjNnW-s If you are unable to make the live webinar, you are invited to register to watch it on-demand as soon as it's available. #OmnichannelCustomerEngagement #MarketAccess #HealthCommunications #OmnichannelTrends #PharmaIndustry #Events

🎷 Did You Know? New Orleans isn't just the birthplace of jazz, it's also the perfect backdrop for bold ideas and meaningful connections. This year, the MAPS Americas Annual Meeting (March 23-26) will bring together over 1,500 Medical Affairs professionals to shape the future of healthcare. Stop by booth 516-- Precision AQ's Medical Communications team will be there, ready to connect and chat about what's next for the industry. 📅 Got a minute? Let's set up a time to share ideas and insights that matter: https://lnkd.in/euJhsTt2 #MAPS2025 #MedicalAffairs #NewOrleans #HealthcareInnovation

Navigating Oncology Market Access: What You Need to Know Getting oncology therapies to the right patients isn't just about approval- it's about understanding the real-world access landscape at leading US cancer centers. OncoGenius provides clarity on how EHR treatment plans, formularies and clinical pathways shape prescribing decisions. Here's what you can uncover: 🏥 Access Insights: How oncology products (yours and competitors') fit into EHR workflows, pathways and formularies at 100+ top cancer centers 💊 Provider Profiles: The role of precision medicine, oral dispensing and institutional workflows in product adoption- before and after launch. 📊 Biomarker & Precision Medicine Trends: How biomarker testing influences treatment selection and where access gaps exist. With these insights, pharma teams can anticipate barriers, align with provider practices and improve patient access. Learn more: https://lnkd.in/ehs9kMBx #OncologyAccess #PrecisionMedicine #OncoGenius #PharmaStrategy

The total cost of care for Alzheimer’s disease and related dementias (ADRD) in the US is projected to increase from $305 billion in 2020 to $2.2 trillion in 2060. Which do you think is the greater burden to caregivers of individuals with ADRD – intangible costs such as lost productivity or tangible costs related to healthcare? Respondents from Precision AQ’s survey of providers and care managers were split ⬇️ Learn more about caring for caregivers in ADRD: https://lnkd.in/e7Tpqkpu

🌟 Exciting Times at the World EPA Congress! 🌟 Our team is on-site at the World EPA Congress today and tomorrow! It's been a fantastic first day with so much more in store for the second half. Here's a quick recap: - We've presented five of our ten posters. Stay tuned for new posters from Precision AQ tomorrow. - Alex Grosvenor and David Carr delivered an insightful presentation on "Global Price Transparency: The What, How & What Now?" with a great turnout of attendees. - We've connected with current and future clients at our booth on the exhibitor floor. Stop by booth 66 to meet our team! If you're at the World EPA Congress, we look forward to connecting with you! #WorldEPACongress #MarketAccess #GlobalPriceTransparency #PharmaMarketing